Business Description
Cyfuse Biomedical KK
ISIN : JP3311800001
Total Employee Number:
26Description
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.86 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | -2.83 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.56 | |||||
Beneish M-Score | -0.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42.8 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 19.6 | |||||
3-Year FCF Growth Rate | 34.6 | |||||
3-Year Book Growth Rate | -16.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.91 | |||||
9-Day RSI | 60.18 | |||||
14-Day RSI | 54.55 | |||||
3-1 Month Momentum % | -15.74 | |||||
6-1 Month Momentum % | -20.66 | |||||
12-1 Month Momentum % | -22.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.55 | |||||
Quick Ratio | 4.44 | |||||
Cash Ratio | 4.25 | |||||
Days Inventory | 1864.42 | |||||
Days Sales Outstanding | 94.23 | |||||
Days Payable | 536.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.3 | |||||
Shareholder Yield % | -18.74 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.35 | |||||
Operating Margin % | -1326.51 | |||||
Net Margin % | -1376.47 | |||||
EBITDA Margin % | -1298.53 | |||||
FCF Margin % | -1728.78 | |||||
OCF Margin % | -1587.58 | |||||
ROE % | -17.71 | |||||
ROA % | -12.04 | |||||
ROIC % | -45.93 | |||||
3-Year ROIIC % | -191.8 | |||||
ROC (Joel Greenblatt) % | -197.42 | |||||
ROCE % | -14.51 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 160.94 | |||||
PB Ratio | 2.04 | |||||
Price-to-Tangible-Book | 2.05 | |||||
EV-to-EBIT | -7.31 | |||||
EV-to-EBITDA | -7.59 | |||||
EV-to-Revenue | 98.49 | |||||
EV-to-FCF | -5.51 | |||||
Price-to-GF-Value | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 2.3 | |||||
| Price-to-Net-Cash | 2.56 | |||||
Earnings Yield (Greenblatt) % | -13.69 | |||||
FCF Yield % | -10.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyfuse Biomedical KK Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 33.686 | ||
| EPS (TTM) (円) | -51.52 | ||
| Beta | -0.6986 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.13 | ||
| Volatility % | 32.61 | ||
| 14-Day RSI | 54.55 | ||
| 14-Day ATR (円) | 17.96971 | ||
| 20-Day SMA (円) | 538.05 | ||
| 12-1 Month Momentum % | -22.17 | ||
| 52-Week Range (円) | 512 - 764 | ||
| Shares Outstanding (Mil) | 9.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyfuse Biomedical KK Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyfuse Biomedical KK Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyfuse Biomedical KK Frequently Asked Questions
What is Cyfuse Biomedical KK(TSE:4892)'s stock price today?
The current price of TSE:4892 is 円563.00. The 52 week high of TSE:4892 is 円764.00 and 52 week low is 円512.00.
When is next earnings date of Cyfuse Biomedical KK(TSE:4892)?
The next earnings date of Cyfuse Biomedical KK(TSE:4892) is .
Does Cyfuse Biomedical KK(TSE:4892) pay dividends? If so, how much?
Cyfuse Biomedical KK(TSE:4892) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cyfuse Biomedical KK
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers